Boston Partners Makes New Investment in Solventum Co. (NYSE:SOLV)

Boston Partners purchased a new position in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,670,408 shares of the company’s stock, valued at approximately $110,378,000. Boston Partners owned approximately 0.97% of Solventum as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in SOLV. Atria Investments Inc raised its stake in shares of Solventum by 93.2% during the third quarter. Atria Investments Inc now owns 11,699 shares of the company’s stock worth $816,000 after acquiring an additional 5,644 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Solventum by 137.3% during the third quarter. Victory Capital Management Inc. now owns 53,589 shares of the company’s stock worth $3,736,000 after acquiring an additional 31,007 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Solventum during the third quarter worth approximately $315,000. CIBC Asset Management Inc raised its stake in shares of Solventum by 7.9% during the third quarter. CIBC Asset Management Inc now owns 19,291 shares of the company’s stock worth $1,345,000 after acquiring an additional 1,408 shares in the last quarter. Finally, Natixis Advisors LLC raised its stake in shares of Solventum by 271.4% during the third quarter. Natixis Advisors LLC now owns 47,616 shares of the company’s stock worth $3,320,000 after acquiring an additional 34,797 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. The Goldman Sachs Group lifted their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Piper Sandler lifted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Wells Fargo & Company lifted their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Finally, Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Stock Performance

NYSE:SOLV opened at $75.38 on Wednesday. The stock has a market cap of $13.04 billion and a P/E ratio of 27.41. The firm’s fifty day simple moving average is $74.77 and its 200 day simple moving average is $71.38. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.